Scribe Therapeutics reported earnings of -$ 0.68 per SCTX share on Nov 12, 2026, falling short of analysts' expectations by
| Report Date | Nov 12, 2026 |
|---|---|
| Forecasted EPS | -$ 0.85 |
| Earnings Per Share (Surprise) | -$ 0.68 (+$ 0.1739) |
Out of the last 2 earnings reporting periods, Scribe Therapeutics beat analysts’ expectations 2 times and fell short of expectations 0 time(s). Scribe Therapeutics reported earnings per share of -$ 0.68 in the last report surpassing an estimated EPS of -$ 0.85 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 0.85 | -$ 0.68 | - | - |
| Sep 2, 2026 | -$ 3.62 | -$ 2.62 | - | - |
Scribe Therapeutics’s stock was trading at $ 16.86 on Nov 11, 2026 a day before the last earnings report was released.Following the release of the earnings report, SCTX’s price decreased to $ 16.36 on Nov 13, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 0.68 | $ 16.86 | $ 16.36 | |
| Sep 2, 2026 | -$ 2.62 | $ 29.00 | $ 30.81 |
Scribe Therapeutics released its most recent earnings reports in November 2026, September 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Scribe Therapeutics beat analysts’ expectations during the last earnings period by
